Remofuscin shown to prevent retinal thinning in Stargardt disease patients

German eye disease specialist Katairo GmbH today announced top-line results of a multi-national, multicenter, double-masked, placebo-controlled, proof of concept trial to evaluate the safety and efficacy of oral Remofuscin (soraprazen) in adults with Stargardt disease.

The Stargardt Remofuscin Treatment Trial (STARTT) was a two-year study comparing remofuscin tablets to placebo. The primary endpoint, quantitative autofluorescence (qAF), a novel method to quantify retinal autofluorescence, proved highly variable and did not show significant changes from baseline in both study groups.

However, Remofuscin treated patients had significantly less retinal thinning on tomographic images (SD-OCT) compared to placebo. This protective effect increased over time and was observed for both eyes.